Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A new fork.Singlepoint's Cannabis Cryptocurrency.A new tailwind for Bitcoin.
What the Fork? Why Bitcoin Tech Changes Impact Price
Bitcoin can be an intimidating place for the new investor.
Scrolling through your news feed, you're more than likely to be greeted by apocalyptic headlines and strange terms – and you might not immediately understand the risks either poses to your investment.
Take the term "forks," for example. They're certainly a pertinent issue without an analogue for more traditional investors. So, what exactly is a fork? And why are they so important to the value of bitcoin and other cryptocurrencies?
The simplest answer is that all cryptocurrencies are software, and that a fork is a change to that software.
When you own an asset like bitcoin, what you really own is just a pair of network password keys. Those keys represent the ability to access the network that keeps track of who owns what and how much.
As such, when that software is modified, it can change the value of user's claims dramatically. In a very real sense, the software itself defines the asset – and, therefore, the price that investors are willing to pay for it.
An example:
While there are many types of forks, most are relatively simple in nature.
A hard fork makes transactions processed on the new software incompatible with the previous versions. In a soft fork, the new version remains backwards compatible.
Earlier this August, bitcoin experienced a high-profile hard fork when a subset of the community split off the software and created a new version called bitcoin cash.
The contention came from bitcoin's move toward a certain scaling upgrade, one which the bitcoin cash contingent was against. With two competing and incompatible "bitcoin" blockchains and "bitcoin" assets, analysts anticipated considerable price volatility, with many believing that prices would trend down.
But, that's not what actually happened.
On August 1, right before the blockchain split, bitcoin was trading at $2,759, according to CoinDesk's Bitcoin Price Index. More than a week later, bitcoin was trading at an all-time high above $4,100. At press time, the price had passed $4,230.
While that might seem odd, several analysts theorized that bitcoin's long-drawn-out scaling debate had posed a major headwind, and its culmination led to a relief rally.
Data shows the bitcoin cash price shooting up to around $700 24 hours after the blockchain split, but because of market dislocations, it's difficult to know how reliable that data is.
In the following two weeks, the price of the new cryptocurrency has mostly hovered between $250 and $300.
The old narrative:
While all this may sound a little wonky, the underlying narrative of headwinds and tailwinds should be familiar to anyone who has invested even casually.
In market terms, a headwind is a risk factor or negative trend that is likely to push prices lower. A tailwind represents just the opposite – a positive movement, a bit of favorable news, or a halo effect caused by some underlying trend.
Headwinds are often discussed when risks come into play that are specific to a company. When the risks diminish, the headwinds are said to subside, and the price of the stock often rises. Stock investors see this sort of rally in the stock market on a fairly regular basis.
The classic example of a headwind is when a company settles a lawsuit or agrees to pay a fine to end a government or regulatory investigation.
Markets despise uncertainty, so when a potentially risky situation gets resolved, investors often see it as a buying opportunity.
In the cryptocurrency space, most analysts have tended to think of forks as a headwind – an event that threatens to destroy value. As such, it's reasonable to expect cryptocurrency prices to rise after the headwind created by a potential fork subsides.
Turning tide:
Yet, this thinking is showing signs of shifting.
Every holder of bitcoin on August 1 had the potential to automatically receive an equal amount of bitcoin cash as part of the fork. So, if bitcoin cash is trading at $300 and bitcoin is trading at $3,000, bitcoin holders have received an additional 10% value because of a software change, all with no additional investment.
But, what if the rise in bitcoin prices after the fork isn't a simple case of an asset price rising because risk has been reduced? What if investors don't see forks as net destroyers of value, which must be discounted with lower prices, but as potential net creators of value?
In this scenario, the total value of bitcoin increases as new cryptocurrencies based on different technologies bloom. When investors hold on to cryptocurrencies in the face of potential forks, it's possible they aren't just weathering a storm, they're emerging from the rain with a richer bouquet of assets in their portfolio
In that case, some forks may be poised to transform into a classic tailwind which could drive prices ever higher.
If we take price to be a reasonable proxy of sentiment, then the forks-create-value view of bitcoin is clearly ascendant right now.
Record Bitcoin Gains Indicate High Times Ahead for Cannabis Cryptocurrency
8:30 am ET August 15, 2017 (PR Newswire) Print
Within America's explosive legal cannabis market-projected to potentially reach a staggering $50 billion valuation by 2026[1]-legal uncertainties and blockades continue to pose challenges. One of these challenges is a lack of banking options for marijuana merchants, who are largely forced to conduct cash transactions, as cannabis businesses currently do not have the backing of the FDIC and, consequently, do not have access to traditional banking options. Necessity is the mother of invention, and enterprising companies are endeavoring to skirt federal restrictions and provide cannabis companies with innovative financial transaction options to meet their growing needs. One company racing to fill this cannabis payment options void is standout player SinglePoint, Inc. (OTC: SING) (SING Profile), which is currently on the fast-track to debuting a payment processing solution utilizing cryptocurrency. This pioneering solution has been developed in collaboration with First Bitcoin Capital Corp. (OTC: BITCF). The validity and promising potential of bitcoin as a solution for marijuana vendors is apparent in view of the staggering success of bitcoin, evidenced in recent gains and in the activities of companies like Bitcoin Services, Inc. (OTC: BTSC), Amazon.com, Inc. (NASDAQ: AMZN) and Overstock.com, Inc. (NASDAQ: OSTK).
As of August 14, bitcoin continued its hike to reach a record high of $4,302.36 per coin. Overall, bitcoin has gained about 80 percent since July and, since the start of 2017, has gained a whopping 257 percent[2]. Such activity clearly shows a promising future for bitcoin and other cryptocurrencies like it.
SinglePoint (OTC: SING) is right at the cutting edge of employing cryptocurrency as a solution for businesses within the cannabis market. The company plans to launch a beta version of its bitcoin solution at the Las Vegas Marijuana Business MJBIZCON event, which takes place November 14-17.
SinglePoint's new bitcoin exchange (http://nnw.fm/Ln5ot) is targeted at providing cannabis businesses with a user-friendly means of accepting debit and credit card payments and will give marijuana consumers the same convenience, allowing them to make purchases with their cards just as they would purchase any item at any other kind of store. SinglePoint has begun developing an in-house solution that would enable marijuana users to obtain bitcoin at any point of sale and to make instant purchases powered by bitcoin when all they have is a debit or credit card. When launched, this solution will be applicable to other markets, as well, and could be deployed by any type of business wishing to offer a bitcoin transaction option-not cannabis companies only.
SinglePoint's bitcoin application will be KYC-AML compliant. Customers will be able to sign up for an account online prior to visiting a merchant, or they can do it in seconds right at the point of sale. Similar solutions have been deployed internationally, but SinglePoint is in an early-mover position to bring such technology to the United States. Though still a few months from its beta launch for the solution, SinglePoint is already amassing potential customers through its website.
SinglePoint recently purchased $Weed from First Bitcoin Capital (OTC: BITCF) and will incorporate this cannabis-specific cryptocurrency into its bitcoin solution, so cannabis dispensaries and consumers can accept/use either bitcoin, $Weed coin or both (http://nnw.fm/M9vYG). The recent initial coin offering (ICO) launch for the $Weed cryptocurrency resulted in an impressive yet illiquid market cap of almost $60 million.
SinglePoint and First Bitcoin Capital plan take a consumer-first approach and heavily invest in getting customers to sign up for cryptocurrency wallets in advance. The benefits of this approach include ensuring customers can make their in-store purchase as quickly as possible, and it will also enable merchants to build in loyalty programs, special offers and more as well as to gain insights regarding which products are being purchased, how many are being sold, etc.
As shown in the broad potential of SinglePoint's cryptocurrency solution, bitcoin has widespread application that includes but also goes far beyond the cannabis market. For more on SinglePoint's operations, visit the company's IR Kit here: http://www.networknewswire.info/sing/ir/
GAP FILLED.UP-UP-UP-WE GO!!!
Any opinions on upcoming hurricane season creating a minor/major NG shortage?
MDCX NEWS:$450M Distribution Agreement
SEATTLE, July 31, 2017 /PRNewswire/ -- MDCorp $MDCX has executed a distribution agreement with Smart Endoscope Systems allowing MDCorp to sell the G-Eye product portfolio throughout their six core European markets.
Neuraxon, currently under M&A with MDCorp is charged with distributing the G-Eye system throughout Europe and their network of 92 hospitals.
Mr. Pantelis Stanitsas stated: "This kind of product distribution win is what we have expected from our M&A partner MDCorp. This win with Smart Endoscope Systems serves to further bind our two companies and our intended M&A which is currently in the process of enhanced due diligence. The G-Eye system should be sold through to our base of 92 hospitals covering an addressable market of 100 million people in six countries. Endoscope related sales in our markets total some $450 million USD annually, and we are particularly enthusiastic about deployment of the new, world class, patented, life-saving technology."
Onsite product training is set to begin in September/October in Israel.
MDCorp seeks to expand into current and new markets, open new branch offices and expand sales, layering more products and services through existing and then new sales channels
"NEWS" $450M Distribution Agreement:
SEATTLE, July 31, 2017 /PRNewswire/ -- MDCorp $MDCX has executed a distribution agreement with Smart Endoscope Systems allowing MDCorp to sell the G-Eye product portfolio throughout their six core European markets.
Neuraxon, currently under M&A with MDCorp is charged with distributing the G-Eye system throughout Europe and their network of 92 hospitals.
Mr. Pantelis Stanitsas stated: "This kind of product distribution win is what we have expected from our M&A partner MDCorp. This win with Smart Endoscope Systems serves to further bind our two companies and our intended M&A which is currently in the process of enhanced due diligence. The G-Eye system should be sold through to our base of 92 hospitals covering an addressable market of 100 million people in six countries. Endoscope related sales in our markets total some $450 million USD annually, and we are particularly enthusiastic about deployment of the new, world class, patented, life-saving technology."
Onsite product training is set to begin in September/October in Israel.
MDCorp seeks to expand into current and new markets, open new branch offices and expand sales, layering more products and services through existing and then new sales channels
"MDCX" News:
SEATTLE, July 31, 2017 /PRNewswire/ -- MDCorp $MDCX has executed a distribution agreement with Smart Endoscope Systems allowing MDCorp to sell the G-Eye product portfolio throughout their six core European markets.
Neuraxon, currently under M&A with MDCorp is charged with distributing the G-Eye system throughout Europe and their network of 92 hospitals.
Mr. Pantelis Stanitsas stated: "This kind of product distribution win is what we have expected from our M&A partner MDCorp. This win with Smart Endoscope Systems serves to further bind our two companies and our intended M&A which is currently in the process of enhanced due diligence. The G-Eye system should be sold through to our base of 92 hospitals covering an addressable market of 100 million people in six countries. Endoscope related sales in our markets total some $450 million USD annually, and we are particularly enthusiastic about deployment of the new, world class, patented, life-saving technology."
Onsite product training is set to begin in September/October in Israel.
MDCorp seeks to expand into current and new markets, open new branch offices and expand sales, layering more products and services through existing and then new sales channels
SEATTLE, July 31, 2017 /PRNewswire/ -- MDCorp $MDCX has executed a distribution agreement with Smart Endoscope Systems allowing MDCorp to sell the G-Eye product portfolio throughout their six core European markets.
Neuraxon, currently under M&A with MDCorp is charged with distributing the G-Eye system throughout Europe and their network of 92 hospitals.
Mr. Pantelis Stanitsas stated: "This kind of product distribution win is what we have expected from our M&A partner MDCorp. This win with Smart Endoscope Systems serves to further bind our two companies and our intended M&A which is currently in the process of enhanced due diligence. The G-Eye system should be sold through to our base of 92 hospitals covering an addressable market of 100 million people in six countries. Endoscope related sales in our markets total some $450 million USD annually, and we are particularly enthusiastic about deployment of the new, world class, patented, life-saving technology."
Onsite product training is set to begin in September/October in Israel.
MDCorp seeks to expand into current and new markets, open new branch offices and expand sales, layering more products and services through existing and then new sales channels
Thanks for info!!!Go MDCX!!!
True!I know.I do!GoMDCX!!!
Amazingly Awesome,update news and bullish chart:
https://finance.yahoo.com/news/efftec-international-inc-announces-financial-110000871.html?.tsrc=rss
I agree.I build my wealth with charts.They are honest pictures of/too reality. "Great Fortunes To Us All"
Again,thanks for info.FTUA!!!
OUCHHH!!!I'll be buying MDCX.We'll keep each other informed now.It's only money. FTUA!!!
That is PGAS year 2015 link:
Weighted average number of common shares outstanding
Basic and diluted 144,188,842 136,000,000
That is 2015;144M
2016:166M
2017:!@#$%^&*()
Thanks for proving my point."+20M yearly share increase".
I knew it!!!Heck with the 10% stake.!@#$%^&*
http://sierraworldequityreview.blogspot.com/2017/07/vote-is-yespfizer-pfe-board-of.html
Also,looking for Pfizer buyout?
http://sierraworldequityreview.blogspot.com/2017/07/vote-is-yespfizer-pfe-board-of.html
The #1 BIOTECH Medical Stock to BUY right now
Backed by a BILLION dollar venture capital group, PMT Advisory, Wall Street's biggest money is behind MDCorp. (MDCX). With deep roots in the under served Asian marketplace, so much success is already anticipated for MDCX as it extends it's reach from Europe into the Asian and Pacific Rim that it is forecast in the future to see what similar well funded start up stocks experienced with institutional buying from biotech-focused hedge fund Baker Bros. Advisors along with two big pharmas, Pfizer (PFE) and Johnson and Johnson (JNJ) who all may also try to buy 10% stakes in private offerings!
"Represents the best Biotech ground floor opportunity for investor's so far in 2017, potentially the best medical stock of 2017, Pfizer, Merck and Roche watch out, there is a new sheriff in town!" Stock Market Rater July 2017.
PGAS Officer's advances
During the year ended December 31, 2016, our Chief Executive Officer advanced the Company $172,100 and was repaid $37,500. As of December 31, 2016, the Company owed the Chief Executive Officer $134,600 (included in Due to Stockholders on the balance sheet presented herein).
Also a $1.8M Dividend was paid.2016 10k F-3
AGREE,Amazing Company.Not sure about the dollar by EOY,that would be nice,but sure does take into favor smt's .20 minimum.
10% stake or may lead to a possible buyout of MDCX.
The #1 BIOTECH Medical Stock to BUY right now
Backed by a BILLION dollar venture capital group, PMT Advisory, Wall Street's biggest money is behind MDCorp. (MDCX). With deep roots in the under served Asian marketplace, so much success is already anticipated for MDCX as it extends it's reach from Europe into the Asian and Pacific Rim that it is forecast in the future to see what similar well funded start up stocks experienced with institutional buying from biotech-focused hedge fund Baker Bros. Advisors along with two big pharmas, Pfizer (PFE) and Johnson and Johnson (JNJ) who all may also try to buy 10% stakes in private offerings!
"Represents the best Biotech ground floor opportunity for investor's so far in 2017, potentially the best medical stock of 2017, Pfizer, Merck and Roche watch out, there is a new sheriff in town!" Stock Market Rater July 2017
I'm thinking(i could be wrong)now that when PGAS R/M w/800Commerce there dept also became PGAS's.There is a lot of flipflopping of 800Commerce's activity going on in PGAS's 10k's, pointing too this.Only logical reason for all the past and present dilution.FTUA!!!
DUHHH ME!Right.Float up to 30M.2nd quarter not out yet.AND dilution here in 3rd quarter.See every year this happens.Float increased over 20M last year.
Not bashing PGAS.Not holding shares,yet again.Providing wise info from past experience here.Give'em your money so I can get it.FTUA!!!
Question:Where did 5M outstanding shares go?10K April 13,2017 O/S-166,795,807;---10QMay 22,2017 O/S-161,016,555.
Just this past month there have been Millions added.Thats what gets me from last year's 10k.There are way more than enough shares to cover there stated dept dumped into O/S structure.GLTA!!!
Yes.WHY?Becouse ive held PGAS shares for 6 months at a time w/no T-Trades..Everytime its starts a run up dilution begins.Or better put,share restructuring.This last run were in,from 2,was a surprise.Missed it.Kept seeing T-TRADES.Is dilution over for the year?Maybe more longs here now,than in the past,as impatient holders sold for a loss to bring it back to .02.
Hope PGAS does not do a Dryships 1-7 RS.
Just curios but what happened to my pix's of PGAS on PGAS board?
As I have done for almost 2 years watch and wait for 10k's and 10q's.
Cant be this year.10k not out till april 2018.
Also true,not a PGAS basher.But yes I may have been a sour grape but now im a sour raisin.Hope it doesn't spread.
True A/S doesn't change the O/S does.Proof of dilution to pay debt is in past two 10k's.O/S increases.Here is proof again:From 10k,
We have raised capital through the use of convertible debt instruments that causes substantial dilution to our stockholders.
Because of the size of our Company and its status as a "penny stock" as well as the current economy and difficulties in companies our size finding adequate sources of funding, we have been forced to raise capital through the issuance of convertible notes and other debt instruments. These debt instruments carry favorable conversion terms to their holders of up to 50% discounts to the market price of our common stock on conversion and in some cases provide for the immediate sale of our securities into the open market. Accordingly, this has caused and will continue to cause dilution to our stockholders in 2016 and may for the foreseeable future. As of December 31, 2015, we had approximately $69,619 in convertible debt and potential convertible debt outstanding. This convertible debt balance as well as additional convertible debt we incur in the future will cause substantial dilution to our stockholders.
Now go read 2016 10k.
Any predictions on what 2017 will be?